IBCSG 61-20 Neo-N

  • This is a randomized phase II trial evaluating the efficacy of a nivolumab monotherapy lead in "window" or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers.

    • Trial Coordinator
      Meredith Kissel

      Monitoring
      ETOP IBCSG Partners Foundation
      Coordinating Center, Bern, Switzerland
      Phone: +41 31 511 94 00
      Fax: +41 31 511 94 01
      Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

      IBCSG Data Management Center/Frontier Science Foundation
      4033 Maple Road
      Amherst, New York 14226 USA
      Phone: +1 716 834 0900
      Fax: +1 716 833 3990
      Email:       This email address is being protected from spambots. You need JavaScript enabled to view it.

       

      Targeted Accrual
      108

      Accrual Closure Date
      April 1, 2022

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    Member Login